Following COPD patients whose blood oxygen drops during exercise
Follows adults with COPD whose blood oxygen falls during exercise, comparing their course with others.
Key facts
- Who runs it
- Universitätsklinikum Hamburg-Eppendorf
- Where
- Hamburg, GermanySee the site
- Trial code
- Registry title
- Intermittent Hypoxemia, Lung Function Decline, Morbidity, and Mortality in COPD (PROSA Study).
- Status
- Not yet recruiting
- People taking part
- 148 people, planned
- Started
- 1 Mar 2024
- Expected to end
- 30 Sept 2029
- Type of study
- Observational, 2 groups
- Treatments tested
- No active intervention, but observational follow-up
- Record updated
- 20 February 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with COPD stages 2-3 (groups B and E) on stable long-acting bronchodilators. They will be followed for 3 years to see how falling oxygen levels during exercise affect the disease.
- Age
- 18 to 80 years
- Sex
- Men and women can join.
- Disease stage
- COPD stages 2-3, groups B and E according to GOLD.
- Earlier treatment
- Must have taken long-acting bronchodilators at a stable dose for at least four months before joining.
Main reasons for not taking part
- Took part in another clinical study in the last 3 months
- Any illness that makes it hard to take part or follow the study plan
- Illness that makes exercise tests risky or hard to do, such as advanced coronary artery disease or advanced chronic heart failure
- Another illness that shortens life expectancy to less than the study time frame
- Pregnant or nursing
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients of both sexes with a diagnosis of chronic obstructive lung disease (COPD) stages 2-3, groups B and E according to GOLD 38 as assessed by their primary family doctor or pneumology specialist who are treated with long-acting bronchodilators on a stable dose for at least four months prior to inclusion into the study
- Age at inclusion 18 - 80 years
- Physical ability and willingness to perform 6-minute walk testing and bicycle ergometry testing
- Signed written informed consent form
Who cannot take part
- Participation in another clinical study within the last 3 months before inclusion into the present study
- Any somatic or psychic disease that may hamper participation in the study or compliance with the study protocol (at the investigator's discretion)
- Any somatic disease that puts the patient at increased risk when performing the exercise tests or impairs the patient's ability to properly perform the exercise tests, like advanced coronary artery disease, advanced chronic heart failure, uncontrolled hypertension, orthopaedic, or neurological diseases (non-exclusive list of examples)
- Any disease or health condition that reduces the patient's life expectancy to less than the expected time frame of this study, other than chronic obstructive lung disease (at the investigator's discretion)
- Pregnancy or nursing
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in Germany
- University Medical Center Hamburg-Eppendorf, Institute of Clinical Pharmacology and ToxicologyHamburg, GermanyContact: Rainer Böger, MDNot yet recruiting
About the trial
What the trial wants to find out
This study aims to analyze if patients with chronic obstructive lung disease who experience a decline of blood oxygen saturation during physical exercise have a disease course different from that of COPD patients who do not experience a decline in blood oxygen saturation during exercise. Patients will be followed for a total of 3 years.
The 2 groups in the trial
- COPD patients with exertional desaturation
Patients with chronic obstructive pulmonary disease stages 2-3, groups B or E according to the GOLD Guideline (2023), who experience a drop in arterial oxygen saturation (by pulse oximetry) to \<90% or a drop by 4% or greater of the basal value during a six-minute walk test.
Treatment: No active intervention, but observational follow-up
- COPD patients without exertional desaturation
Patients with chronic obstructive pulmonary disease stages 2-3, groups B or E according to the GOLD Guideline (2023), who do not experience a drop in arterial oxygen saturation (by pulse oximetry) to \<90% or a drop by 4% or greater of the basal value during a six-minute walk test.
Treatment: No active intervention, but observational follow-up
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective Observational Study to Assess the Influence of Intermittent Hypoxaemia on Lung Function Decline, Morbidity, and Mortality in COPD Patients (PROSA Study)
- Plain-language title
- Following COPD patients whose blood oxygen drops during exerciseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06265623, who can take part
- Publications
- Record updated
- 20 February 2024